Alzheimer disease

JAMA

Volumn 287, Issue 18, 2002, Pages 2335-2338

  Cummings, Jeffrey L ^a   Cole, Greg ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; APOLIPOPROTEIN E4; CHOLINESTERASE INHIBITOR; DONEPEZIL; ESTROGEN; GALANTAMINE; GINKGO BILOBA EXTRACT; PSYCHOTROPIC AGENT; RIVASTIGMINE; SELEGILINE; TACRINE;

AGING; ALLELISM; ALZHEIMER DISEASE; CLINICAL FEATURE; COGNITION; DAILY LIFE ACTIVITY; DRUG CHOICE; DRUG INDICATION; EPIDEMIOLOGICAL DATA; GENETIC PREDISPOSITION; GENETIC RISK; HEALTH CARE COST; HUMAN; INCIDENCE; NERVE DEGENERATION; PATHOPHYSIOLOGY; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; REVIEW; SOCIAL SUPPORT; TREATMENT OUTCOME;

EID: 0037042299     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.287.18.2335     Document Type: Review

References (50)

1. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset
2. Aging and the occurrence of dementia
3. The relationships between age, sex, and the incidence of dementia and Alzheimer disease
4. The US economic and social costs of Alzheimer's disease revisited
5. The economic impact of Alzheimer's disease
6. Apolipoprotein E4 allele and the lifetime risk of Alzheimer's disease
7. Statement on use of apolipoprotein E testing for Alzheimer disease
8. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease
9. Education and other measures of socioeconomic status and risk of incident Alzheimer disease in a defined population of older persons
10. Risk factors for late-onset Alzheimer's disease
11. Head injury and the risk of AD in the MIRAGE study
12. Rates and risk factors for dementia and Alzheimer's disease
13. Dietary fat intake and the risk of incident dementia in the Rotterdam study
14. Wine consumption and dementia in the elderly
15. Incidence of dementia and Alzheimer disease in 2 communities
16. Documentation and evaluation of cognitive impairment in elderly primary care patients
17. Minimental state
18. Practice parameter: Early detection of dementia
19. The spectrum of behavioral responses in cholinesterase inhibitor therapy in Alzheimer disease
20. Clinical diagnosis of Alzheimer's disease
21. Factors affecting course and survival in Alzheimer disease
22. Cause of death in Alzheimer's disease
23. Practice parameter: Diagnosis of dementia (an evidence-based review)
24. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease
25. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease
26. Alzheimer's disease
27. The neuropathology of Alzheimer's disease
28. Amyloid, the presenilins and Alzheimer's disease
29. Molecular genetics of Alzheimer's disease
30. Presenilins, β-amyloid precursor protein and the molecular basis of Alzheimer's disease
31. Formation of neurofibrillary tangles in P301 transgenic mice induced by Abeta 42 fribrils
32. Practice parameter: Management of dementia (an evidence-based review)
33. A 24 week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
34. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
35. A 5-month, randomized, placebo-controlled trial of galantamine in AD
36. Cholinesterase inhibitors: A new class of psychotropic agents
37. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease
38. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease
39. Estrogen for Alzheimer's disease in women
40. Histamine H2 blocking drugs and the risk for Alzheimer's disease
41. Risk of Alzheimer's disease and duration of NSAID use
42. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors
43. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia
44. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities
45. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia
46. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease
47. A double-blind, randomized, fixed-dose trial of fluoxetine vs amitriptyline in the treatment of major depression complicating Alzheimer's disease